| Hepatitis C
Hepatitis C is a specific type of virus that may cause the clinical disease called hepatitis. It is referred to as the hepatitis C virus (HCV). Hepatitis (literally, inflammation of the liver) can be caused by many drugs, toxic agents, numerous viruses, autoimmune disease, and genetic disorders. Description Hepatitis (literally, inflammation of the liver) can be caused by many drugs, toxic agents, numerous viruses, autoimmune disease, and genetic disorders. Infection with the hepatitis C virus (HCV) poses a significant public health problem, the magnitude of which may match or eventually exceed that of hepatitis B virus (HBV) in the United States. In the United States, more than 36,000 people a year are infected with HCV. Hepatitis C accounts for more than 90 percent of non-A, non-B hepatitis cases attributable to intravenous drug use, transfusion, and other percutaneous (through the skin) exposures.
All Brains Are the Same Color
And others who later made the same argument Richard Herrnstein and Charles Murray in "The Bell Curve," in 1994, for example, and just recently, William Saletan in a series of articles on Slate have made the same mistake. In fact, the evidence heavily favors the view that race differences in I.Q. are environmental in origin, not genetic. The hereditarians begin with the assertion that 60 percent to 80 percent of variation in I.Q. is genetically determined. However, most estimates of heritability have been based almost exclusively on studies of middle-class groups. For the poor, a group that includes a substantial proportion of minorities, heritability of I.Q. is very low, in the range of 10 percent to 20 percent, according to recent research by Eric Turkheimer at the University of Virginia.
Top police officer warns that nuclear attack is inevitable
More than 300 experts from 70 countries were taking part in a high-level meeting organised by the UN International Atomic Energy Agency on the risks of nuclear terrorism. The police response to a CBRN incident when it happened would have a "profound effect on our communities which should not be underestimated", he said. The protective clothing that officers would have to wear would look "terrifying". As Dickinson made the point in his speech on Wednesday, one of his fellow police officers appeared dramatically on the stage dressed head to toe in a regulation black protection suit. With his face completely obscured by a gas mask, the officer then walked slowly through the delegates seated in the Edinburgh International Conference Centre. Decontamination after a radiation attack would be an "enormous cost", Dickinson contended.
Israeli 'Guided Missiles' Induce Cancer Cells To Commit Suicide
For a moment, Dr. Shai Yarkoni, president and CEO of biotechnology start-up Target-In, appears to veer off on a tangent. "There's something very interesting in the terms we take from the military to the medical world and vice versa," he says contemplatively. "Surgical strike, magic bullets, these are all phrases that pass from one industry to the other."
People call what Target-In is doing 'guided missiles', and in a way that's exactly what the company's technology is: a guided missile that can recognize and kill inflamed cells from tumors and other diseases. But Target-In's technology is more sophisticated than that. The technology doesn't just shoot diseased cells down, it makes them commit suicide.
Target-in was founded in 2002 and stems from over 10 years of academic research by Prof.
Biotech firms courting investors
For 11 years, TransMolecular Inc. has been working on a promising brain cancer treatment from a substance found in scorpion venom. Now TransMolecular, which has already raised $43 million in venture capital, hopes to raise additional funding as it embarks on pivotal clinical trials to prove the drug is safe and effective - a critical step needed to win approval to market the drug in the United States. "For the last two years, we've tried to keep our head down," said TransMolecular chief executive E. Michael Egan. "Now it's time to put our heads back up." TransMolecular, based in Cambridge, is one of about three dozen local biotech companies slated to speak at the Massachusetts Biotechnology Council's annual investor conference in Boston Thursday, an opportunity for small to midsize growth companies to court potential investors and partners.
In French suburbs, same rage, but new tactics
We are a French family with roots in the immigration. My wife's father came from Sardinia before WWII, when Italy was still a poor country. I am very surprised by some comments that were posted that France is a racist country! This is too simple and really stupid a conclusion. Do you really think it was that easy for earlier waves of immigrants, Polish, Italian, Portuguese people? They didn't get any help from the State (no subsidized houses at that time, called HLM here), they were looked down by the rest of the population. When you are an immigrant everywhere in the word, you're looked a different way. This is true in Europe, in the States in the Arab world or Africa. You need to be really better than everyone, work harder! The current wave of immigration is no exception to this, those people work hard just like the earlier waves from Southern Europe.
Ricky Williams reinstated, Dolphins get 2-week roster exemption
DAVIE, Fla. (AP) -- Ricky Williams' suspension ended after more than 18 months when he was reinstated Wednesday by the NFL, and the winless Miami Dolphins might welcome him back.The 2002 league rushing champion was scheduled to fly to South Florida for a physical Thursday and meet with coach Cam Cameron, said Williams' agent, Leigh Steinberg.The first-year Miami coach, whose team is 0-9, said he talked with Williams by phone for "five or six minutes" Wednesday, but hadn't made a decision about activating him."I want to see where he is, and also let him know where we're headed, and we'll go from there," Cameron said.Cameron has been mum for months regarding whether he would want Williams back. But Steinberg said he was encouraged by a phone conversation Wednesday with Matt Thomas, Dolphins general counsel-football administration."His indication was they were interested in Ricky," Steinberg said.
Missing Protein Provides Clue To Ovarian Cancer Drug Success, UK
Scientists have discovered a protein which could improve the success rate of the tumour shrinking drug paclitaxel, in the treatment of ovarian cancer, a study reveals in Cancer Cell.
The researchers, funded by Cancer Research UK and the Medical Research Council, found that the loss of a protein called TGFBI caused paclitaxel to fail.
Paclitaxel, part of a family of drugs called taxanes - originally derived from yew trees - is a common chemotherapy treatment for ovarian cancer. However, only 50 per cent of patients respond well to the therapy.
The authors, based at Cambridge Research Institute, at Cambridge University, examined ovarian cancer cell lines and data from 20 patients in a prospective trial. Those who showed no response to the drug had less TGFBI in their pre-treatment samples compared to those whose condition improved.
|
